Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAGBiotechnology
+$2.32 today
- Market cap
- $1.83B
- Beta
- 0.00
Volume 0.30M
Average 0.34M
COAG Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Hemab Therapeutics Holdings, Inc. Common StockNASDAQ: COAG
Net Debt · Q2 FY2026 · quarter ended Jun 2026
Net debt of -$236.34M in Q2 FY2026
Q2 FY2026 net debt was -$236.34M.
Context
- Net debt amounted to 50.5% of total assets at the end of Q2 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (86.75M) USD
- Year-over-year change
- —
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (86.75M) | — |
Net Debt vs competitors
How COAG compares with its peers on the latest reported figures
- COAG's Jun 2026 net debt of -$236.34M is the 4th highest of the 5 companies compared; the peer median is -$58.91M.
- Net debt amounts to 50.5% of total assets for COAG, versus a peer median of 42.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
IRONDisc Medicine, Inc. | Sep 2026 | -$28.9M | +73.7% | — | 4.1% |
| Mar 2026 | -$41.15M | -180.6% | — | 75.5% | |
| Mar 2026 | -$76.67M | +49.2% | — | 9.8% | |
COAGHemab Therapeutics Holdings, Inc. Common Stock | Jun 2026 | -$236.34M | — | — | 50.5% |
DMRADamora Therapeutics, Inc. | Mar 2026 | -$531.56M | -4959.6% | — | 99.3% |
| Peer median (excluding COAG) | -$58.91M | -65.7% | — | 42.7% | |
Competitors are the stored peer set for COAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAG
Intrinsic Alpha fair value
Locked
Current Price
$39.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.